Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan
| العنوان: | Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan |
|---|---|
| المؤلفون: | Miyazaki, Celine, Masuda, Junya, Rodriguez-Rey, Mateo Delclaux, Stelmaszuk, Marta Natalia, Freilich, Jonatan, Tsai, Phiona I-Ching, Saeki, Hidehisa |
| المصدر: | Journal of dermatological treatment (Print). 35(1) |
| مصطلحات موضوعية: | Biologics, healthcare resource utilization, psoriasis, treatment pattern |
| الوصف: | Background: With advent of newer treatments for psoriasis, real-world use of biologics in Japan is evolving.Methods: This retrospective study utilized data from patients with ≥1 psoriasis-related biologic claims record between January 2016 and December 2020 in Japan to evaluate treatment patterns, healthcare resource utilization (HCRU), and associated costs. Data were analyzed using descriptive statistics.Results: Of 1,614 eligible patients, 72.5% were male, 29.2% had comorbid hypertension and 26.6% had comorbid cardiovascular disease. Interleukin (IL)-17 and tumor necrosis factor alpha (TNFα) inhibitors were commonly prescribed across lines of treatment, while IL-23 inhibitors were most considered for switches (92% of switches were from IL-12/23/IL-17/TNFα inhibitors). The overall mean adherence rate for all classes was 80.1%, but adherence varied across biologics. Infliximab and IL-23 inhibitor users exhibited optimal medical possession ratios, reflecting the best adherence rates. Overall HCRU (visits/patient-year) was 9.05 for outpatient visits, 0.09 for inpatient hospitalization, and 0.5 for psoriasis-related phototherapy. HCRU associated with hospitalization was slightly higher for bio-experienced patients and so was the overall costs per patient-year relative to bio-naïve patients.Conclusion: Variable adherence rates observed suggest the need for improvement in treatment management with different biologics. Bio-experienced patients burdened by disease progression and treatment switches may result in increased HCRU. |
| وصف الملف: | electronic |
| URL الوصول: | https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-221056 https://doi.org/10.1080/09546634.2023.2299598 https://umu.diva-portal.org/smash/get/diva2:1838928/FULLTEXT01.pdf |
| قاعدة البيانات: | SwePub |
PDF full text from Publisher | تدمد: | 09546634 14711753 |
|---|---|
| DOI: | 10.1080/09546634.2023.2299598 |